Hematopoietic stem cells (HSCs) are rare cells that have the unique ability to self-renew and differentiate into cells of all hematopoietic lineages. The lack of donors and current inability to rapidly and efficiently expand HSCs are key roadblocks in the development of successful cell therapies. Thus the challenge of ex-vivo human HSC expansion remains a fertile and critically important area of investigation. Here we show that either SALL4A-or B-transduced human HSCs obtained from the mobilized peripheral blood are capable of rapid and efficient expansion ex vivo by more than 10,000 fold for both CD34+/CD38-and CD34+/CD38+ cells in the presence of appropriate cytokines. We found that the expanded cells retained hematopoietic precursor cell immunophenotypes and morphology as well as normal in vitro or vivo potential for differentiation. The SALL4 mediated expansion was associated with enhanced stem cell engraftment and long-term repopulation capacity in vivo. In addition, we demonstrated that constitutive expression of SALL4 inhibited granulocytic differentiation and permitted expansion of undifferentiated cells in 32D myeloid progenitors, consistent with the known function of SALL4 in the ES (embryonic stem) cell system. Furthermore, a TAT-SALL4B fusion was able to rapidly expand CD34+ cells, and it is thus feasible to translate this study into the clinical setting. Our findings provide a new avenue for investigating mechanisms of stem cell self renewal and achieving clinically significant expansion of human HSCs.
Introduction
HSCs, which are rare cells capable of differentiating into blood lineages, have been identified in fetal bone marrow and liver, umbilical cord blood, adult bone marrow, and peripheral blood.
HSCs are used in clinical transplantation protocols to treat a variety of diseases including leukemia, inborn anomalies of the blood and immune system, aplastic anemia, and hemoglobinopathies. However, finding a matching donor is difficult, time-consuming, and especially problematic for African-Americans, Hispanics, Native Americans and people of mixed ethnicity. Currently, only one in three patients will find a suitable donor and, as a result, many patients die before finding an appropriate match.
The lack of donors and the current inability to rapidly and efficiently expand HSCs are key roadblocks in the development of successful therapies. Investigators have been trying to expand human HSCs for the last three decades, but have not succeeded in a clinically meaningful way.
Thus the challenge of ex vivo human HSC expansion remains a fertile and critically important area of investigation. Clinical trials have employed cord blood-derived HSCs expanded through Notch ligands 1 , stromal co-culture 2 and automated, continuous perfusion culture systems, or 'bioreactors' 3 . Other approaches to expand HSCs include the use of aryl hydrocarbon receptor antagonists 4 and transduction of NF-Ya to activate HOXB4 using cell-penetrating peptides such as TAT 5 . Of these techniques, the highest expansion efficiencies have been obtained with Notch signaling 1 , which produced a 160-fold increase in CD34+ cells compared to controls; however, long-term engraftment was not achieved 1, 6 . Therefore, identification of additional potent HSC expanding factors and development of a robust method for expansion of HSCs from the bone marrow or cord blood is urgently needed for bone marrow transplantation and genetic therapy 7 .
For personal use only. on July 15, 2017 . by guest www.bloodjournal.org From SALL4 is a zinc-finger transcriptional factor and a member of the SALL gene family, originally cloned based on their DNA-sequence homolog to Drosophila homeotic gene, sal 8, 9 . Recently, our group and others have shown that the embryonic stem cell (ESC) factor, SALL4, plays a vital role in maintaining ES cell pluripotency and in governing decisions affecting the fate of ES cells through transcriptional modulation and interaction with Oct4 and Nanog [10] [11] [12] [13] [14] [15] [16] . We have demonstrated that SALL4 is expressed constitutively in human leukemia cell lines and primary AML cells [17] [18] [19] [20] [21] . To our best knowledge, SALL4 may be one of a few genes creating a connection between leukemic stem cells, and the self-renewal properties of normal HSCs and ESCs 10, [18] [19] [20] .
In the present work, we demonstrate that SALL4 is a robust stimulator for the expansion of human HSCs. We demonstrated that overexpression of SALL4 isoforms ex vivo leads to more than a 10,000 fold expansion of human HSCs in the presence of appropriate cytokines. More importantly, these expanded HSC cells were associated with enhanced stem cell repopulation capacity in vivo. Finally, we developed a recombinant TAT-SALL4B protein that is capable of human HSC expansion ex vivo. Our findings may shed new light on investigating mechanisms of stem cell self renewal and achieving clinically significant expansion of human HSCs.
For personal use only. on July 15, 2017 . by guest www.bloodjournal.org From
Methods

SALL4-lentiviral infection of human CD34+ cells
Normal human bone marrow CD34+ cells were purchased (AllCells, Emeryville, CA, USA) and single cell suspensions were generated in StemSpan SFEM (Stem Cell Technologies, Vancouver, BC, Canada) for 24 hours. Next, 10 5 cells/well were placed in a 12-well plate. The cells were cultured in StemSpan SFEM containing 10%FBS and 1%pen/strep (Gibco, Carlsbad, CA, USA).
The media was supplemented with 100ng/ml FLT-3, 100ng/ml TPO and 100ng/ml SCF (ProSpec, Rehovet, Israel). SALL4 lentivirus particles at an MOI between 10-20 were added to the bone marrow cells at 37°C. For controls, GFP-only lentivirus particles were added to the bone marrow cells at similar MOIs. The cells were infected overnight for 12-15hours then recovered in culture medium.
Expansion of SALL4-transduced human CD34+ cells
The SALL4-transduced CD34+ cells were expanded in 12-well plates under normal culture conditions (StemSpan SFEM containing 10%FBS and 1%pen/strep supplemented with 100ng/ml FLT-3, 100ng/ml TPO and 100ng/ml SCF). In addition, cells were cultured in more stringent conditions in which recombinant cytokine concentrations were decreased to see if the SALL4-transduced cells were still capable of surviving and expanding. In one experiment, cells were cultured in media containing 50% less cytokines (50ng/ml FLT-3, 50ng/ml TPO and 50ng/ml SCF). In an additional trial, cells were cultured in media containing 75% less growth factors (25ng/ml FLT-3, 25ng/ml TPO and 25ng/ml SCF). Cells were monitored for two months and observed with bright field and fluorescent microscopy. mm petri dish and a third, uncovered 35 mm dish containing 3 mL of sterile water was also added. All 3 dishes were then covered within the 100 mm petri dish. The cells were incubated for 14-18 days at 37°C with 5% CO2 and ≥ 95% humidity. The BFU-E, CFU-GM and CFU-GEMM colonies were observed with bright field and fluorescent microscopy. CFUs were counted under the microscope 13-18 days after the cells were plated in MethoCult® medium. A colony with more than 100 cells was counted as a positive colony.
Expansion of SALL4-transduced isolated CD34+ cells from patient samples
Flow cytometry and phenotyping of cells
Flow cytometry was conducted with Phycoerythrin (PE)-conjugated antibody to CD34 and CD19, allophycocyanin (APC)-conjugated antibody to CD38,CD15, and CD33, and PerCPCy5.5-conjugated antibody to CD45 for cell sorting (BD Biosciences, Franklin Lakes, NJ, USA).
The presence of human cells in NOD-SCID mouse bone marrow was determined using CD45-PE antibody. Myeloid cells were tracked by CD15-APC or CD33-APC antibody and lymphoid cells were tracked by CD19-PE or CD3-PE antibody. 
Serially transplanted studies
Mice BM cells were harvested from the tibiae and femurs of highly engrafted primary recipient mice 16 weeks post-transplantation. After removal of red blood cells by lysis buffer, half of the 
Expression and purification of His-TAT-SALL4A/B
For expression of TAT-SALL4 in E. coli, the human SALL4B gene was doubly digested with the restriction endonucleases SalI and NotI, and ligated into a pTAT-pET28b vector, a 6xHis-taq protein expression vector bearing the T7 promoter, kanamycin resistance and pTAT Peptide/Protein Transducing Domain (PTD). The plasmids with the correct gene sequences were then transformed into E. coli strain BL21 (DE3). The 6xHis-fused human SALL4B was expressed with 0.1 mM IPTG induction for 3 h and then purified by using a Ni-NTA affinity column (Qiagen). The purity of the purified His-TAT-SALL4B was further determined based on
SDS-PAGE and LC-MS/MS.
SDS-PAGE and Western blot
Proteins were loaded on 12.5% one-dimensional SDS-PAGE for protein separation, followed by staining with Coomassie brilliant blue R-250 and destained in 10% methanol/ 7% acetic acid.
For Western blot analysis, the SDS-PAGE was transferred to poly-(vinylidene difluoride) (PVDF) membranes (Millipore). After transfer, the membranes were saturated with 5% w/v nonfat dry milk in TBS/0.1% Tween 20 at 4°C overnight, followed by incubation with the primary antibodies overnight at 4˚C. Primary antibodies against human SALL4 and 6xHis-tag were purchased from Abcam (Cambridge, UK). After three washes with TBS/0.1% Tween 20, For personal use only. on July 15, 2017. by guest www.bloodjournal.org From the membranes were incubated with a solution of peroxidase-conjugated secondary antibodies (Abcam, Cambridge, UK). After 1-h incubation at room temperature, the membranes were washed three times with TBS/0.1% Tween 20 and the membrane blots were developed by using ECL substrates (Millipore).
In-gel digestion and LC-MS/MS
Gel bands were cut and digested in-gel with trypsin. Peptides were resuspended in 50 µl 0.1% formic acid/2% acetonitrile. 10 µl of the peptide was injected into Orbitrap at Stony Brook University Proteomics Center for 1D LC/MS/MS analysis.
Statistical analysis
Results are reported as means + s.d. Values with p < 0.05 were considered to be statistically significant.
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Results
Robust ex vivo expansion of human HSCs by overexpression of SALL4 isoforms
A series of experiments were carried out to determine the effects of SALL4 isoforms on hematopoietic precursors, human bone marrow CD34+ cells. The cells were transduced with lentiviruses expressing either SALL4A or SALL4B cDNAs that were combined with a GFP reporter gene to facilitate isolation and tracking of transduced cells. SALL4A and B are two splicing isoforms generated through internal splicing ( Figure 1A Figure 3C ). The expansion experiments were repeated at least 12 times using a variety of sources for the CD34+ cells (supplemental Table 1 ). In all trials, the SALL4A or SALL4 B transduced human CD34 cells were able to expand in the liquid culture medium for more than 2 months and demonstrated similar percentages of cell populations (15% CD34+/CD38-, 17% CD34+/CD38+) to 31-day old cells demonstrated by flow cytometry.
The expansion of SALL4 transduced cells occurred quite rapidly with significant CD34+ cell growth in just a few days. In order to see if SALL4 induced clusters could serve as a seed for further expansion, single cell clusters were picked from the parental plate and placed into individual wells of a 48-well plate. The cluster was gently dissociated by repeated aspiration with a pipette tip. The next day new small GFP positive cell clusters began to form again (supplemental Figure 3) . These clusters were allowed to expand for 5 days and began to grow at a similar rate as seen in the initial parental plates.
In order to determine if SALL4 was able to expand CD34+ cells under stringent conditions, we conducted cell cultures in which recombinant growth factor concentrations were decreased to 50 or 25% of cytokines for both SALL4 induced HSCs and control cells. Cell growth was monitored during the first week. Interestingly, cells transduced with SALL4A or SALL4B were still able to survive and expand beyond 7 days of culture ( Figures 2C,2D and 3A) . In contrast, control cells had ceased to proliferate and expansion slowed by day 7 ( Figure 3A) . In other experiments, SALL4-transduced cells were grown in culture with various combinations of the For personal use only. on July 15, 2017. by guest www.bloodjournal.org From growth factors SCF, TPO, and FLT-3L, which have been reported to be present at low levels in the marrow niche. After 14 days of culture, it was noted that the SALL4-transduced cells growth and survival were independent of FLT-3L, partially dependent of TPO, and dependent of SCF (supplemental Table 2 ). This finding is potentially important because the niche in the normal marrow does not bear excessive special cytokines and is delicately regulated, unlike the high artificial levels in our cell cultures. This study may indicate that SALL4 works in conjunction with the available cytokine levels in its environment to regulate cell expansion.
Blocking differentiation and permitting proliferation by SALL4 isoforms
To investigate the mechanism by which SALL4 effects stem cell growth and identity, we extended our studies to the myeloid progenitor cell line, 32D. 
Functional analysis of SALL4 induced CD34+ cells in vitro
To further study the proliferation potential of the SALL4-transduced HSCs without an excess of special cytokines, colony-forming unit (CFU) assays were conducted. The CFU progenitors used for the study were initially GFP-positive signifying the expression of SALL4 protein ( Figure 5A) and were cultured for at least one month in media containing the cytokines SCF, TPO, and FLT-3L. The CFU assays, conducted in methocult media without these cytokines, revealed that these cells could form various colonies including CFU-GM, CFU-GEMM, and BFU-E ( Figure 5B ). In addition, the one month-old transduced cells had the capability to form similar numbers of CFU colonies compared to 2-day old GFP-transduced control cells when counted 18 days after the CFU assay was initialized ( Figure 5C and 5D ). This study indicates that SALL4 works in conjunction with other cytokines in order to block HSC differentiation; therefore, other cytokines are needed to inhibit differentiation.
To further test whether the transfer of SALL4 can lead to the long term expansion of human hematopoietic progenitors, we cultured SALL4A-and SALL4B-transduced cells for one month.
After 31 days of culture there was a 1780-fold for SALL4A and 1463-fold for SALL4B increase in total CD34+ cells numbers compared to controls ( Figure 6A ) (control cells ceased to expand after 10 to 12 days). Furthermore, SALL4 transduced cells showed 9.32 fold increases for SALL4A and 8.88 fold increases for SALL4B versus controls for the total number of LTC-ICs after one month ( Figure 6B ). Overall, SALL4A transduced cells had a total fold CD34+/CD38-stem cell expansion 16700 over control while SALL4B transduced cells showed 13300 fold increases although there was not a statistically significant difference between the two SALL4 isoforms ( Figure 6C 
Expansion was associated with enhanced stem cell repopulation capacity in vivo
To test if SALL4 mediated cells are able to override the regulatory machinery in the marrowniche to control their differentiation, repopulation capacity, and stem cell output, we performed xenotransplantation assays. Phenotypic analysis revealed that both SALL4A-(n=9) and SALL4B-transduced (n=10) cells were capable of positive cell engraftment into NOD/SCID mice ( Figure 6D for SALL4A and 1 in 9,100 (range defined by +/-s.e.: 6,700-12,400) for SALL4B. The total SRC content was expanded by 1080 fold for SALL4A and 844 fold for SALL4B (n=72) compared to uncultured cells by taking into account the increase in the SRC frequencies and total cell numbers ( Figure 6H ). Our results suggest that overexpression of SALL4 solely in HSCs does not override the regulatory mechanisms involved in the control of stem cell output in vivo.
TAT-SALL4B protein induced CD34+ cell expansion
Lentiviral expression of SALL4 is very efficient, but its clinical application is not ideal due to difficulties in controlling the level and duration of expression of the transgene in vivo as well as the potential for insertional leukemogenesis. Protein transduction utilizing cell penetrating peptides can overcome the limitations of lentiviral vectors and has been widely used recently 5, 23, 24 . In order to use a different approach to demonstrate the role of SALL4 in HSC expansion, we produced TAT-6xHis-SALL4B protein expressed in E. coli, and purified using Ni-NTA agarose (supplemental Figures 5A and 5B) . The recombinant protein of TAT-SALL4B was confirmed by a Western blot with a anti-6xHis tag mouse monoclonal antibody and mass spectrometry analysis (supplemental Figures 5C and 5D ). We focused on SALL4B because it is a shorter form and expressed a high level of protein in E. coli. After 3 days of TAT-SALL4B treatment, the CD34+ cells expanded rapidly ( Figure 7A ). Human CD34+ cells cultured 3 to 4 days with SALL4 fusion protein (200nM) along with TPO, SCF and Flt-3 ligand showed more than 10 and 8 fold increases of total mononuclear cells and CD34+ cells, respectively ( Figures   7B and 7C ). TAT-SALL4B protein (200nM) was added twice a day and appeared to be sufficient to expand the cells. In addition, CFU assays demonstrated that these cells could form various colonies including CFU-GM, CFU-GEMM, and BFU-E ( Figure 7D and 7E) . By taking the fold increase of the TAT-SALL4B treated cells versus control times the CFU numbers, it was noted that the overall CFU number increased by approximately ten fold.
Discussion
We have developed a new therapeutic strategy using cytokine-dependent SALL4 technology for the dramatic 10,000 to 15,000-fold ex vivo expansion of human HSCs without significant differentiation over 4 weeks. In addition, even after 8 weeks of cell culture, 37% of the CD34+ cells were still CD34+/CD38-(data not shown). In xenotransplantation models, the stem cell frequency of cells that had been induced by SALL4 for 4 weeks ex vivo was only 2-2.5-fold higher than fresh CD34+ cells ( Figure 6H ). This is consistent with our own results showing that SALL4 expansion is cytokine-dependent (supplemental Table 2 ), although the total SRC content was quite high (expanded by 1080 fold for SALL4A and 844 fold for SALL4B). Thus, the in vivo growth of SALL4-induced HSCs might be dissimilar to those in cell culture conditions (ex vivo) where an excess of special cytokines is present. In vivo growth is dependent on the tissue niche (supplemental Table 2 & Figure 6 ) consistent with the findings of other HSC expanding factors, HOXB4 and Notch signaling.
Like other approaches used for HSC expansion, the SALL4-transduced cells growth and survival were dependent of special cytokines. The magnitude of HSC expansion is unprecedentedly high with 10,000 fold for CD34+ /CD38-and CD34+/ CD38+ populations, and seems to be far superior to existing approaches such as Notch ligands that demonstrated only 160 fold increases for the CD34+ population . In addition, the expansion of engraftable long-term HSCs by our SALL4 approach seemed to be achievable and was supported by evidence of the secondary and tertiary transplantation studies. In contrast, the two main approaches for HSC expansion utilizing Hoxb4 and Notch ligands do not 1, 6 .
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From Our current findings may be extremely valuable for clinical therapy. Massive ex vivo expansion of CD34+ cells can be achieved without differentiation. These expanded cells retain long-term engraftment properties similar to those of un-manipulated cells in vivo. The SALL4-expanded cells sustained a long-term engraftment demonstrated by serial xenotransplant models and repopulation assays. Most critically, after transplantation they do not override the niche-induced regulatory controls, allowing these expanded stem cells to avoid leukemic formation. In our studies, no evidence of leukemia was evident in transplanted mice in either serially xenotransplanted animals or by more than 10 months post-transplantation (n=12), although additional long-term follow up is needed (data not shown). In addition, no leukemic formation was exhibited for 12 months post syngeneic transplantation when either SALL4A or B was expressed and introduced into mouse stem/progenitor hematopoietic cells (n=6). However, in our previous transgenic mouse studies of SALL4B overexpression controlled by a universal promoter, CMV, there was an increased incidence of leukemic formation in older mice 17 . Yet this phenotype was not seen with SALL4A overexpression (N=170, five transgenic mouse lines, data not shown) after 2 years of observation. This could be due to an abnormal niche resulting from dysregulated SALL4B expression with this universal CMV promoter and/or SALL4B may bear oncogenic potential. A further study should be conducted to explore this possibility. As an interesting note, Notch signaling has been used for expansion of HSCs and the expanded cells have been used in human clinical trials. Notch signaling is also involved in a variety of cancer stem cells since both cancer and adult stem cells share functional properties in self renewal.
Nevertheless, we have developed a safer approach; a TAT-SALL4 protein to avoid constitutive expression of SALL4. CD34+ cells exposed to this TAT-SALL4 protein were able to rapidly expand ex vivo. In the future, it will be important to optimize TAT-fusion protein technology,
This may open a new avenue to study the mechanisms of stem cell self renewal and achieve clinically significant expansion of human HSCs for therapy. may be through inhibiting differentiation and permitting proliferation. Furthermore, CD34+ cells exposed to the TAT-SAB protein were able to rapidly expand ex vivo. In the future, it will be important to 
